News GRI Bio, Inc.

Equities

GRI

US3622AW3040

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-07-01 pm EDT			5-day change	1st Jan Change
1.64 ^USD	-13.68%		-10.38%	-95.32%

Jul. 02	GRI Bio, Inc. Announces Publication of Positive Preclinical Data from Lead Program GRI -0621 in the American Journal of Respiratory and Critical Care Medicine	CI
May. 21	GRI Bio, Inc Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GRI Bio, Inc. Announces Publication of Positive Preclinical Data from Lead Program GRI -0621 in the American Journal of Respiratory and Critical Care Medicine	Jul. 02	CI
GRI Bio, Inc Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus	May. 21	CI
GRI Bio, Inc. Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis	May. 20	CI
GRI Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T Cell Modulators with Issuance of Korea Patent	Apr. 16	CI
GRI Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
GRI Bio, Inc. Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom	Mar. 04	CI
GRI Bio's Board Approves 1-for-7 Reverse Stock Split to Regain Nasdaq Compliance	Jan. 26	MT
GRI Bio Announces Reverse Stock Split	Jan. 26	AQ
GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment	Dec. 06	AQ
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)	Dec. 05	AQ
GRI Bio, Inc. Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for Treatment of Idiopathic Pulmonary Fibrosis	Dec. 05	CI
GRI Bio Secures FDA Clearance for Investigational New Drug Application for Pulmonary Fibrosis Treatment	Nov. 27	MT
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)	Nov. 27	AQ
GRI Bio, Inc. Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis	Nov. 27	CI
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 15	AQ
GRI Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases	23-10-31	AQ
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference	23-10-19	AQ
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression	23-10-17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News GRI Bio, Inc.

Equities

GRI

US3622AW3040

Summary

Filters